• Vaccine Name: CAdVax-Filoviruses (Ebola )
• Target Pathogen: Ebola virus
• Target Disease: Ebola hemorrhagic fever
• Vaccine Ontology ID: VO_0004644
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: Baboon
• Vector:
  • Vector name:
  • VO vector ID: VO_0001086
• Preparation: A panfilovirus vaccine based on a complex adenovirus (CAdVax) technology that expresses multiple antigens from five different filoviruses de novo (Swenson et al., 2008).
• Immunization Route: Intramuscular injection (i.m.)

Macaque Response

• Vaccination Protocol: The macaques in the vaccine groups (five per group) were anesthetized by intramuscular injection of ketamine HCl (10 mg/kg of body weight), followed by intramuscular vaccination with an equal mixture of 1 × 10^10 PFU of each vaccine component: EBO2, EBO7, M8, and M11 (resulting in 4 × 10^10 total PFU per animal). Control animals received 4 × 10^10 PFU of the HC4 vaccine vector, also via the intramuscular route (Swenson et al., 2008).
• Vaccine Immune Response Type: VO_0000287
• Challenge Protocol: Group 1 was inoculated subcutaneously with MARV Musoke, while group 2 was inoculated intramuscularly with ZEBOV, using approximately 1,000 PFU of each filovirus. EBOV and MARV each have different established routes of administration (intramuscular and subcutaneous, respectively) (Swenson et al., 2008).
• Efficacy: All vaccinated animals showed no detectable viremia or hematology abnormalities. We can conclude that the multivalent filovirus vaccine was 100% protective against lethal MARV Musoke and ZEBOV challenges (Swenson et al., 2008).